Clinical Observation of Entecavir in Treatment of HBeAg Positive Patients with Hepatitis B

Objective: To investigate efficacy and safety of entecavir on treatment of hepatitis B with positive HBeAg.Methods: 140 patients with chronic hepatitis B were randomly divided into 2 groups: study group were treated with entecavir 0.5 mg/d,and the control group were given lamivudine 100 mg/d.Both of the course was 48 weeks.HBV DNA negative conversion rates,ALT normaliza-tion rate,HBeAg seroconversion rates and incidence of adverse reactions were observed.Results: After 12 weeks of treatment,HBV DNA negative conversion rate of the observation and control group were 47.1% and 22.9%(P 0.01),respectively.ALT normalization rate were 51.4% and 31.4%(P 0.05),respectively.After 48 weeks of treatment,HBV DNA negative conversion rate of the observation and control group were 88.6% and 48.6%(P 0.01),respectively.ALT normalization rate were 90.0% and 72.9%(P 0.01),respectively.HBeAg seroconversion between the two groups were no significant difference.No serious adverse events occurred in the both groups.Conclusion: Compared with lamivudine,entecavir shows more rapid onset,stronger efficacy,and safety on treatment of hepatitis B with positive HBeAg.